Press

2023-03-21

The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145

Kancera AB (publ) today reports that the Japan patent office has issued a patent that protects the manufacturing processes for Kancera’s Fractalkine blocking drug candidates KAND567 and KAND145.

Read More
2023-03-01

Kancera reports that patient enrollment to the FRACTAL-study is completed and that top line results will be presented in Q3 2023

Kancera AB (publ) today reports that the patient enrollment to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, has been completed and that a total of 71 patients have been recruited. Kancera aims to...

Read More
2023-02-16

Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer

Kancera AB (publ) today reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study, a clinical study of KAND567 in ovarian cancer patients. The company further reports organizational changes, including the appointment of a...

Read More
2023-01-30

Kancera provides operational update for its Fractalkine-blocking drug candidates KAND567 and KAND145

Kancera AB (publ) today reports that the clinical studies of its Fractalkine-blocking drug candidates KAND567 and KAND145 are progressing according to plans and that the US patent office has issued a patent that protects the manufacturing processes.

Read More
2023-01-16

Kancera reports that the FRACTAL-study is on track to report top line results in Q3 2023

Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of 60 study subjects in total. Kancera has previously announced...

Read More
2022-05-23

Kancera provides operational update in connection with the interim report for the first quarter of 2022

This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.

Read More
2022-05-20

Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851

First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022·        Net sales amounted to SEK 0 million (SEK 0.0 million).·        R&D costs amounted to SEK 10,6 million (8,2 million).·        Operating...

Read More
2021-11-22

Kancera’s drug candidate KAND145 effectively reduces tumor size in a preclinical model of ovarian cancer

This is a translation of press release in Swedish (2021-11-22). Kancera AB (Nasdaq First North Premier Growth Market: KAN) today presents preclinical results that show that KAND145 effectively reduces tumor size in a disease model of ovarian cancer. These...

Read More
2021-11-19

Kancera reports top-line data from the phase IIa study with KAND567 in COVID-19 patients

This is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with KAND567 in patients with COVID-19. The randomized double-blinded study...

Read More
2021-06-16

Kancera has completed patient recruitment for the COVID-19 study with KAND567

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent of the originally planned number of COVID-19 patients have...

Read More